Why the study?
MicroRNAs are investigated for their role in cardiovascular pathogenesis, but evidence for their clinical implementation in heart failure is still lacking.
Are microRNAs reliable pathophysiological and diagnostic biomarkers in patients with heart failure?
Population
Heart failure patients and control groups across studies in PubMed
Comparison
Heart failure patients vs control groups
Design
Systematic review
Authors
Loading...
Inconsistent miRNA signatures across HF studies caution against clinical biomarker use; leaves open the need for standardized prospective validation.
Are microRNAs reliable pathophysiological and diagnostic biomarkers in patients with heart failure?
Current evidence does not support the routine clinical use of circulating microRNAs as diagnostic or prognostic biomarkers in heart failure.
Peterlin et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: